Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9022
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrosh-Nissimov, Tal-
dc.contributor.authorMa’aravi, Nir-
dc.contributor.authorLeshin-Carmel, Daniel-
dc.contributor.authordkk.-
dc.date.accessioned2024-12-14T05:00:55Z-
dc.date.available2024-12-14T05:00:55Z-
dc.date.issued2024-02-
dc.identifier.issn1684-1182-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9022-
dc.description.abstractWe present a retrospective study on the treatment outcomes of severely immunocompromised patients with persistent COVID-19. The study analyzed data from 14 patients who received a combination of tixegavimab/cilgavimab and antiviral medications. Response was evaluated based on symptom improvement, PCR cycle-threshold values, and C-reactive protein levels. Eleven patients achieved complete clinical and virological resolution, while three showed partial responses. The study suggests a potential association between non-response and tixegavimab/cilgavimab neutralization. The findings underscore the need for tailored treatment approaches and further research on optimal strategies for managing persistent COVID-19, as well as the development of antivirals and variant-specific monoclonal antibodies.en_US
dc.language.isoen_USen_US
dc.publisherJournal of Microbiology, Immunology and Infectionen_US
dc.relation.ispartofseriesShort Communication;189-194-
dc.subjectCOVID-19en_US
dc.subjectImmunocompromiseden_US
dc.subjectTixegavimab/ cilgavimaben_US
dc.subjectRemdesiviren_US
dc.subjectNirmatrelviren_US
dc.titleCombination treatment of persistent COVID-19 in immunocompromised patients with remdesivir, nirmaltrevir/ritonavir and tixegavimab/cilgavimaben_US
dc.typeArticleen_US
Appears in Collections:Vol. 57 No. 1 (2024)

Files in This Item:
File Description SizeFormat 
189-194.pdf623.92 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.